In particular, Derks et al. [27], showed that patients with RB1 wild-type (WT) LCNEC treated with NSCLC chemotherapy regimens had a significantly longer overall survival, compared to patients treated with SCLC chemotherapy regimens (9.6 vs. 5.8, respectively). This evidence concerns the gene RB1 and non-small cell lung carcinoma.